{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T07:09:11Z","timestamp":1793257751731,"version":"4.5.0"},"reference-count":130,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,7,26]]},"abstract":"<jats:p>Blast crisis (BC) remains the major challenge in the management of chronic myeloid leukemia (CML). It is now generally accepted that BC is the consequence of continued BCR-ABL activity leading to genetic instability, DNA damage, and impaired DNA repair. Most patients with BC carry multiple mutations, and up to 80% show additional chromosomal aberrations in a nonrandom pattern. Treatment with tyrosine kinase inhibitors has improved survival in BC modestly, but most long-term survivors are those who have been transplanted. Patients in BC should be treated with a tyrosine kinase inhibitor according to mutation profile, with or without chemotherapy, with the goal of achieving a second chronic phase and proceeding to allogeneic stem cell transplantation as quickly as possible. Although long-term remissions are rare, allogeneic stem cell transplantation provides the best chance of a cure in BC. Investigational agents are not likely to provide an alternative in the near future. In view of these limited options, prevention of BC by a rigorous and early elimination of BCR-ABL is recommended. Early response indicators should be used to select patients for alternative therapies and early transplantation. Every attempt should be made to reduce or eliminate BCR-ABL consistent with good patient care as far as possible.<\/jats:p>","DOI":"10.1182\/blood-2012-03-380147","type":"journal-article","created":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T04:58:26Z","timestamp":1338526706000},"page":"737-747","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":237,"title":["How I treat CML blast crisis"],"prefix":"10.1182","volume":"120","author":[{"given":"R\u00fcdiger","family":"Hehlmann","sequence":"first","affiliation":[{"name":"III Medizinische Klinik, Medizinische Fakult\u00e4t Mannheim, Ruprecht-Karls-Universit\u00e4t, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"23","key":"2019111822434659800_B1","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"issue":"15","key":"2019111822434659800_B2","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.","volume":"349","author":"Hughes","year":"2003","journal-title":"N Engl J Med"},{"issue":"4","key":"2019111822434659800_B3","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/ajh.2830010414","article-title":"Evaluation of survival data for chronic myelocytic leukemia.","volume":"1","author":"Sokal","year":"1976","journal-title":"Am J Hematol"},{"issue":"2","key":"2019111822434659800_B4","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1517\/14656566.2011.533169","article-title":"Treatment of chronic myeloid leukemia when imatinib fails.","volume":"12","author":"Hehlmann","year":"2011","journal-title":"Expert Opin Pharmacother"},{"issue":"12","key":"2019111822434659800_B5","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.3324\/haematol.2008.001214","article-title":"Treatment of chronic myeloid leukemia in blast crisis.","volume":"93","author":"Hehlmann","year":"2008","journal-title":"Haematologica"},{"issue":"3","key":"2019111822434659800_B6","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.beha.2009.07.006","article-title":"The blast phase of chronic myeloid leukaemia.","volume":"22","author":"Silver","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"issue":"3","key":"2019111822434659800_B7","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1182\/blood.V32.3.445.445","article-title":"Characteristics of the terminal phase of chronic granulocytic leukemia.","volume":"32","author":"Karanas","year":"1968","journal-title":"Blood"},{"issue":"35","key":"2019111822434659800_B8","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"key":"2019111822434659800_B9","article-title":"Chronic myelogenous leukemia, BCR-ABL1 positive.","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Vardiman","year":"2008","edition":"4th Ed"},{"issue":"6","key":"2019111822434659800_B10","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1002\/cncr.21756","article-title":"Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal.","volume":"106","author":"Cortes","year":"2006","journal-title":"Cancer"},{"issue":"5","key":"2019111822434659800_B11","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood-2010-12-326405","article-title":"BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.","volume":"118","author":"Soverini","year":"2011","journal-title":"Blood"},{"issue":"1","key":"2019111822434659800_B12","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/ijc.2910180105","article-title":"Non-random karyotypic evolution in chronic myeloid leukemia.","volume":"18","author":"Mitelman","year":"1976","journal-title":"Int J Cancer"},{"issue":"1","key":"2019111822434659800_B13","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0165-4608(87)90131-2","article-title":"The karyotype of blastic crisis.","volume":"26","author":"Alimena","year":"1987","journal-title":"Cancer Genet Cytogenet"},{"issue":"2","key":"2019111822434659800_B14","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1159\/000046636","article-title":"Cytogenetic and molecular genetic evolution of chronic myeloid leukemia.","volume":"107","author":"Johansson","year":"2002","journal-title":"Acta Haematol"},{"issue":"26","key":"2019111822434659800_B15","doi-asserted-by":"crossref","first-page":"6760","DOI":"10.1182\/blood-2011-08-373902","article-title":"Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV.","volume":"118","author":"Fabarius","year":"2011","journal-title":"Blood"},{"issue":"8","key":"2019111822434659800_B16","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/sj.leu.2403426","article-title":"Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance.","volume":"18","author":"Hochhaus","year":"2004","journal-title":"Leukemia"},{"issue":"18","key":"2019111822434659800_B17","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.1200\/JCO.2005.05.531","article-title":"ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia.","volume":"23","author":"Soverini","year":"2005","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019111822434659800_B18","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood.V84.8.2391.2391","article-title":"Structure and function of p53 in normal cells and their aberrations in cancer cells: projection on the hematologic cell lineages.","volume":"84","author":"Prokocimer","year":"1994","journal-title":"Blood"},{"issue":"8","key":"2019111822434659800_B19","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1182\/blood.V85.8.2013.bloodjournal8582013","article-title":"Homozygous deletions of the p16 tumor-suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia.","volume":"85","author":"Sill","year":"1995","journal-title":"Blood"},{"issue":"3","key":"2019111822434659800_B20","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/leu.2010.298","article-title":"A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases.","volume":"25","author":"Grossmann","year":"2011","journal-title":"Leukemia"},{"issue":"7","key":"2019111822434659800_B21","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1182\/blood-2007-07-102533","article-title":"RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL(+) leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance.","volume":"111","author":"Roche-Lestienne","year":"2008","journal-title":"Blood"},{"issue":"7191","key":"2019111822434659800_B22","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature06866","article-title":"BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros.","volume":"453","author":"Mullighan","year":"2008","journal-title":"Nature"},{"issue":"6","key":"2019111822434659800_B23","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/sj.leu.2404227","article-title":"Gene expression profiling of CD34+ cells identifies a molecular signature of chronic myeloid leukemia blast crisis.","volume":"20","author":"Zheng","year":"2006","journal-title":"Leukemia"},{"issue":"8","key":"2019111822434659800_B24","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1073\/pnas.0510423103","article-title":"Gene expression changes associated with progression and response in chronic myeloid leukemia.","volume":"103","author":"Radich","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"2019111822434659800_B25","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1056\/NEJMoa040258","article-title":"Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML.","volume":"351","author":"Jamieson","year":"2004","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111822434659800_B26","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1365-2141.1990.tb07832.x","article-title":"A study of prognostic factors in blast crisis of Philadelphia chromosome-positive chronic myelogenous leukaemia.","volume":"76","author":"Cervantes","year":"1990","journal-title":"Br J Haematol"},{"issue":"7","key":"2019111822434659800_B27","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1182\/blood.V99.7.2304","article-title":"Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemia.","volume":"99","author":"Wadhwa","year":"2002","journal-title":"Blood"},{"issue":"14","key":"2019111822434659800_B28","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","article-title":"Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"issue":"2","key":"2019111822434659800_B29","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cancergencyto.2007.10.006","article-title":"Specific clones of spontaneously evolving karyotypes generate individuality of cancers.","volume":"180","author":"Fabarius","year":"2008","journal-title":"Cancer Genet Cytogenet"},{"issue":"13","key":"2019111822434659800_B30","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.4161\/cc.10.13.16352","article-title":"Is carcinogenesis a form of speciation?","volume":"10","author":"Duesberg","year":"2011","journal-title":"Cell Cycle"},{"issue":"6","key":"2019111822434659800_B31","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/nrc2147","article-title":"Chronic myeloid leukaemia as a model of disease evolution in human cancer.","volume":"7","author":"Melo","year":"2007","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"2019111822434659800_B32","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/asheducation-2007.1.384","article-title":"The biology of CML blast crisis.","author":"Radich","year":"2007","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"7","key":"2019111822434659800_B33","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1172\/JCI41246","article-title":"Chronic myeloid leukemia: mechanisms of blastic transformation.","volume":"120","author":"Perrotti","year":"2010","journal-title":"J Clin Invest"},{"issue":"5","key":"2019111822434659800_B34","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/nrc799","article-title":"Oncogenic tyrosine kinases and the DNA-damage response.","volume":"2","author":"Skorski","year":"2002","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"2019111822434659800_B35","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood-2005-07-2815","article-title":"BCR\/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance.","volume":"108","author":"Koptyra","year":"2006","journal-title":"Blood"},{"issue":"12","key":"2019111822434659800_B36","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1182\/blood-2004-05-1941","article-title":"BCR\/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks.","volume":"104","author":"Nowicki","year":"2004","journal-title":"Blood"},{"issue":"10","key":"2019111822434659800_B37","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1182\/blood-2009-01-197186","article-title":"Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.","volume":"114","author":"Soverini","year":"2009","journal-title":"Blood"},{"issue":"32","key":"2019111822434659800_B38","doi-asserted-by":"crossref","first-page":"24273","DOI":"10.1074\/jbc.M002094200","article-title":"The BCR\/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells.","volume":"275","author":"Sattler","year":"2000","journal-title":"J Biol Chem"},{"key":"2019111822434659800_B39","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3109\/10428199609074374","article-title":"Current aspects of drug therapy in Philadelphia-positive CML: correlation of tumor burden with survival.","volume":"22","author":"Hehlmann","year":"1996","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2019111822434659800_B40","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro.","volume":"99","author":"Graham","year":"2002","journal-title":"Blood"},{"issue":"12","key":"2019111822434659800_B41","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1182\/blood-2007-03-080838","article-title":"Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors.","volume":"110","author":"Cortes","year":"2007","journal-title":"Blood"},{"issue":"12","key":"2019111822434659800_B42","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1200\/JCO.2010.32.0598","article-title":"Tolerability-adapted imatinib 800 mg\/d versus 400 mg\/d versus 400 mg\/d plus interferon-alpha in newly diagnosed chronic myeloid leukemia.","volume":"29","author":"Hehlmann","year":"2011","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111822434659800_B43","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1182\/blood.V38.6.671.671","article-title":"Hematologic and cytogenetic remission of blastic transformation in chronic granulocytic leukemia.","volume":"38","author":"Canellos","year":"1971","journal-title":"Blood"},{"issue":"1","key":"2019111822434659800_B44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000208322","article-title":"The treatment of terminal metamorphosis of chronic granulocytic leukaemia with corticosteroids and vincristine.","volume":"50","author":"Marmont","year":"1973","journal-title":"Acta Haematol"},{"issue":"4","key":"2019111822434659800_B45","first-page":"542","article-title":"Blast crisis of chronic granulocytic leukemia: morphologic variants and therapeutic implications.","volume":"63","author":"Rosenthal","year":"1977","journal-title":"Am J Hematol"},{"issue":"15","key":"2019111822434659800_B46","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1056\/NEJM197804132981503","article-title":"Terminal transferase as a predictor of initial responsiveness to vincristine and prednisone in blastic chronic myelogenous leukemia.","volume":"298","author":"Marks","year":"1978","journal-title":"N Engl J Med"},{"issue":"7","key":"2019111822434659800_B47","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1200\/JCO.1986.4.7.1079","article-title":"High-dose cytosine arabinoside: treatment and cellular pharmacology of chronic myelogenous leukemia blast crisis.","volume":"4","author":"Iacoboni","year":"1986","journal-title":"J Clin Oncol"},{"issue":"12","key":"2019111822434659800_B48","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1002\/(SICI)1097-0142(19991215)86:12<2632::AID-CNCR7>3.0.CO;2-A","article-title":"Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients.","volume":"86","author":"Sacchi","year":"1999","journal-title":"Cancer"},{"issue":"10","key":"2019111822434659800_B49","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","article-title":"Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.","volume":"99","author":"Sawyers","year":"2002","journal-title":"Blood"},{"issue":"10","key":"2019111822434659800_B50","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1182\/blood.V99.10.3547","article-title":"Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase.","volume":"99","author":"Kantarjian","year":"2002","journal-title":"Blood"},{"issue":"11","key":"2019111822434659800_B51","first-page":"1213","article-title":"Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia.","volume":"88","author":"Sureda","year":"2003","journal-title":"Haematologica"},{"issue":"12","key":"2019111822434659800_B52","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.3324\/haematol.13068","article-title":"Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up.","volume":"93","author":"Palandri","year":"2008","journal-title":"Haematologica"},{"issue":"21","key":"2019111822434659800_B53","first-page":"52","article-title":"Initial findings from the PACE trial: a pivotal phase 2 study of ponatinib in patients with CML and Ph+ ALL resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation [abstract].","volume":"118","author":"Cortes","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"24","key":"2019111822434659800_B54","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.","volume":"354","author":"Talpaz","year":"2006","journal-title":"N Engl J Med"},{"issue":"12","key":"2019111822434659800_B55","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1038\/leu.2008.221","article-title":"Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase.","volume":"22","author":"Cortes","year":"2008","journal-title":"Leukemia"},{"issue":"16","key":"2019111822434659800_B56","doi-asserted-by":"crossref","first-page":"3852","DOI":"10.1002\/cncr.25123","article-title":"Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily.","volume":"116","author":"Saglio","year":"2010","journal-title":"Cancer"},{"issue":"4","key":"2019111822434659800_B57","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1182\/blood-2008-02-140665","article-title":"Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia.","volume":"112","author":"Porkka","year":"2008","journal-title":"Blood"},{"issue":"24","key":"2019111822434659800_B58","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N Engl J Med"},{"issue":"5","key":"2019111822434659800_B59","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/leu.2011.355","article-title":"Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase.","volume":"26","author":"Giles","year":"2012","journal-title":"Leukemia"},{"key":"2019111822434659800_B60","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/978-3-642-01222-8_9","article-title":"Bosutinib.","volume-title":"Small Molecules in Oncology","author":"Keller","year":"2010"},{"issue":"4","key":"2019111822434659800_B61","first-page":"513","article-title":"Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).","volume":"91","author":"Gratwohl","year":"2006","journal-title":"Haematologica"},{"issue":"10","key":"2019111822434659800_B62","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1182\/blood-2009-08-237115","article-title":"Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV.","volume":"115","author":"Saussele","year":"2010","journal-title":"Blood"},{"issue":"20","key":"2019111822434659800_B63","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.1182\/blood-2011-07-367326","article-title":"Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias.","volume":"118","author":"Nicolini","year":"2011","journal-title":"Blood"},{"issue":"3","key":"2019111822434659800_B64","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.beha.2009.05.002","article-title":"Current role of stem cell transplantation in chronic myeloid leukaemia.","volume":"22","author":"Gratwohl","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"issue":"2","key":"2019111822434659800_B65","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1182\/blood-2005-05-1816","article-title":"Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate.","volume":"107","author":"Jabbour","year":"2006","journal-title":"Blood"},{"issue":"2","key":"2019111822434659800_B66","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/bmt.2010.69","article-title":"The EBMT activity survey 2008: impact of team size, team density and new trends.","volume":"46","author":"Gratwohl","year":"2011","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"2019111822434659800_B67","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/cncr.22535","article-title":"Imatinib combined with mitoxantrone\/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis.","volume":"109","author":"Fruehauf","year":"2007","journal-title":"Cancer"},{"issue":"5","key":"2019111822434659800_B68","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/cncr.22470","article-title":"Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia.","volume":"109","author":"Oki","year":"2007","journal-title":"Cancer"},{"issue":"2","key":"2019111822434659800_B69","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1080\/10428190601075973","article-title":"A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase.","volume":"48","author":"Quint\u00e1s-Cardama","year":"2007","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"2019111822434659800_B70","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1002\/cncr.22901","article-title":"Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib.","volume":"110","author":"Cortes","year":"2007","journal-title":"Cancer"},{"issue":"11","key":"2019111822434659800_B71","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s00277-010-0991-4","article-title":"Standard-dose imatinib plus low-dose homoharringtonine and granulocyte colony-stimulating factor is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis who have failed prior single-agent therapy with imatinib.","volume":"89","author":"Fang","year":"2010","journal-title":"Ann Hematol"},{"issue":"21","key":"2019111822434659800_B72","first-page":"276","article-title":"A phase 1 study of DCC-2036, a novel oral inhibitor of BCR-ABL kinase, in patients with Philadelphia chromosome positive (Ph+) leukemias including patients with T315I mutation [abstract].","volume":"118","author":"Cortes","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"5","key":"2019111822434659800_B73","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ccr.2005.10.015","article-title":"The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR\/ABL-regulated SET protein.","volume":"8","author":"Neviani","year":"2005","journal-title":"Cancer Cell"},{"issue":"24","key":"2019111822434659800_B74","doi-asserted-by":"crossref","first-page":"6660","DOI":"10.1182\/blood-2010-08-304477","article-title":"Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression.","volume":"117","author":"Lucas","year":"2011","journal-title":"Blood"},{"issue":"9","key":"2019111822434659800_B75","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1172\/JCI31095","article-title":"FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.","volume":"117","author":"Neviani","year":"2007","journal-title":"J Clin Invest"},{"issue":"21","key":"2019111822434659800_B76","first-page":"1603","article-title":"A novel SET antagonist (OP449) is cytotoxic to CML cells, including the highly-resistant BCR-ABLT315I mutant, and demonstrates enhanced efficacy in combination with ABL tyrosine kinase inhibitors [abstract].","volume":"118","author":"Agarwal","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"7347","key":"2019111822434659800_B77","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/nature09883","article-title":"BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition.","volume":"473","author":"Duy","year":"2011","journal-title":"Nature"},{"issue":"11","key":"2019111822434659800_B78","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1084\/jem.20110304","article-title":"BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia.","volume":"208","author":"Hurtz","year":"2011","journal-title":"J Exp Med"},{"issue":"15","key":"2019111822434659800_B79","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1182\/blood-2008-07-168773","article-title":"A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo.","volume":"113","author":"Cerchietti","year":"2009","journal-title":"Blood"},{"issue":"11","key":"2019111822434659800_B80","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1182\/blood-2011-10-387381","article-title":"HIF1alpha is required for survival maintenance of chronic myeloid leukemia stem cells.","volume":"119","author":"Zhang","year":"2012","journal-title":"Blood"},{"issue":"7239","key":"2019111822434659800_B81","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/nature07737","article-title":"Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia.","volume":"458","author":"Zhao","year":"2009","journal-title":"Nature"},{"issue":"3","key":"2019111822434659800_B82","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ccr.2008.08.003","article-title":"Expansion of Bcr-Abl-positive leukemic stem cells is dependent on hedgehog pathway activation.","volume":"14","author":"Dierks","year":"2008","journal-title":"Cancer Cell"},{"issue":"21","key":"2019111822434659800_B83","first-page":"1613","article-title":"Cycling toward leukemia stem cell elimination with a selective sonic hedgehog antagonist [abstract].","volume":"118","author":"Shih","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"12","key":"2019111822434659800_B84","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1056\/NEJMoa0905360","article-title":"Inhibition of the Hedgehog pathway in advanced basal-cell carcinoma.","volume":"361","author":"Von Hoff","year":"2009","journal-title":"N Engl J Med"},{"issue":"21","key":"2019111822434659800_B85","first-page":"737","article-title":"Combination targeted therapy to impair self-renewal capacity of human blast crisis leukemia stem cells [abstract].","volume":"118","author":"Court Recart","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"37","key":"2019111822434659800_B86","doi-asserted-by":"crossref","first-page":"16280","DOI":"10.1073\/pnas.1004408107","article-title":"Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein.","volume":"107","author":"J\u00e4r\u00e5s","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"2019111822434659800_B87","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1158\/1535-7163.MCT-09-0386","article-title":"Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells.","volume":"8","author":"Mak","year":"2009","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"2019111822434659800_B88","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/leu.2011.285","article-title":"Activation of apoptosis signaling eliminates CD34+ progenitor cells in blast crisis CML independent of response to tyrosine kinase inhibitors.","volume":"26","author":"Mak","year":"2012","journal-title":"Leukemia"},{"issue":"7","key":"2019111822434659800_B89","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1038\/leu.2011.67","article-title":"The MEK inhibitor PD184352 enhances BMS-214662-induced apoptosis in CD34+ CML stem\/progenitor cells.","volume":"25","author":"Pellicano","year":"2011","journal-title":"Leukemia"},{"issue":"5","key":"2019111822434659800_B90","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/leu.2011.7","article-title":"p53 stabilization induces apoptosis in chronic myeloid leukemia blast crisis cells.","volume":"25","author":"Peterson","year":"2011","journal-title":"Leukemia"},{"issue":"4","key":"2019111822434659800_B91","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1177\/1947601910372232","article-title":"Destabilization of Bcr-Abl\/Jak2 network by a Jak2\/Abl kinase inhibitor ON044580 overcomes drug resistance in blast crisis chronic myelogenous leukemia (CML).","volume":"1","author":"Samanta","year":"2010","journal-title":"Genes Cancer"},{"issue":"22","key":"2019111822434659800_B92","first-page":"267","article-title":"Safety and efficacy of subcutaneous-administered omacetaxine mepesuccinate in imatinib-resistant chronic myeloid leukemia (CML) patients who harbor the Bcr-Abl T315I mutation: results of an ongoing multicenter phase 2\/3 Study [abstract].","volume":"114","author":"Cortes-Franco","year":"2009","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"2019111822434659800_B93","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1053\/j.seminoncol.2007.12.002","article-title":"Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia.","volume":"35","author":"Giles","year":"2008","journal-title":"Semin Oncol"},{"issue":"5","key":"2019111822434659800_B94","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/leu.2008.47","article-title":"Experimental non-ATP-competitive therapies for chronic myelogenous leukemia.","volume":"22","author":"Quint\u00e1s-Cardama","year":"2008","journal-title":"Leukemia"},{"key":"2019111822434659800_B95","doi-asserted-by":"crossref","first-page":"S395","DOI":"10.3816\/CLM.2009.s.040","article-title":"The next generation of therapies for chronic myeloid leukemia.","volume":"9","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"issue":"6","key":"2019111822434659800_B96","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1182\/blood.V82.6.1929.1929","article-title":"Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation.","volume":"82","author":"Cross","year":"1993","journal-title":"Blood"},{"issue":"10","key":"2019111822434659800_B97","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1182\/blood-2005-08-3320","article-title":"Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy.","volume":"107","author":"Kaeda","year":"2006","journal-title":"Blood"},{"issue":"19","key":"2019111822434659800_B98","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1182\/blood-2010-03-273979","article-title":"Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS).","volume":"116","author":"Hughes","year":"2010","journal-title":"Blood"},{"issue":"11","key":"2019111822434659800_B99","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"issue":"4","key":"2019111822434659800_B100","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.bloodjournal634789","article-title":"Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic leukemia.","volume":"63","author":"Sokal","year":"1984","journal-title":"Blood"},{"issue":"11","key":"2019111822434659800_B101","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","article-title":"A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa: Writing Committee for the Collaborative CML Prognostic Factors Project Group.","volume":"90","author":"Hasford","year":"1998","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"2019111822434659800_B102","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2010-12-319038","article-title":"Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score.","volume":"118","author":"Hasford","year":"2011","journal-title":"Blood"},{"issue":"11","key":"2019111822434659800_B103","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1182\/blood-2009-02-204693","article-title":"Chronic myeloid leukemia (CML) with P190BCR-ABL: analysis of characteristics, outcomes, and prognostic significance.","volume":"114","author":"Verma","year":"2009","journal-title":"Blood"},{"issue":"1","key":"2019111822434659800_B104","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1182\/blood-2006-12-065599","article-title":"The polycomb group BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia.","volume":"110","author":"Mohty","year":"2007","journal-title":"Blood"},{"issue":"5","key":"2019111822434659800_B105","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1002\/1097-0142(19870901)60:5<974::AID-CNCR2820600510>3.0.CO;2-1","article-title":"Sequential karyotype study on Ph-positive chronic myelocytic leukemia: significance of additional chromosomal abnormalities during disease evolution.","volume":"60","author":"Krulik","year":"1987","journal-title":"Cancer"},{"issue":"6","key":"2019111822434659800_B106","first-page":"515","article-title":"Prognostic value of atypical chromosomal changes during chronic myeloid leukemia.","volume":"72","author":"Geraci","year":"1987","journal-title":"Haematologica"},{"issue":"4","key":"2019111822434659800_B107","first-page":"628","article-title":"The relationship between secondary chromosomal abnormalities and blast transformation in chronic myelogenous leukemia.","volume":"9","author":"Anastasi","year":"1995","journal-title":"Leukemia"},{"issue":"1","key":"2019111822434659800_B108","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1200\/JCO.1996.14.1.196","article-title":"Significance of cytogenetic clonal evolution in chronic myelogenous leukemia.","volume":"14","author":"Majlis","year":"1996","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111822434659800_B109","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/sj.leu.2402813","article-title":"Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate.","volume":"17","author":"Schoch","year":"2003","journal-title":"Leukemia"},{"issue":"3","key":"2019111822434659800_B110","first-page":"260","article-title":"Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progression.","volume":"88","author":"Marktel","year":"2003","journal-title":"Haematologica"},{"issue":"10","key":"2019111822434659800_B111","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1182\/blood-2002-09-2790","article-title":"Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy.","volume":"101","author":"Cortes","year":"2003","journal-title":"Blood"},{"issue":"2","key":"2019111822434659800_B112","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1182\/blood-2003-02-0371","article-title":"Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate.","volume":"103","author":"O'Dwyer","year":"2004","journal-title":"Blood"},{"issue":"6","key":"2019111822434659800_B113","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1182\/blood-2005-03-1036","article-title":"High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy.","volume":"106","author":"Willis","year":"2005","journal-title":"Blood"},{"issue":"3","key":"2019111822434659800_B114","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/leu.2009.222","article-title":"Similar patterns of chromosome abnormalities in CML occur in addition to the Philadelphia chromosome with or without tyrosine kinase inhibitor treatment.","volume":"24","author":"Haferlach","year":"2010","journal-title":"Leukemia"},{"issue":"11","key":"2019111822434659800_B115","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1002\/cncr.25015","article-title":"Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy.","volume":"116","author":"Verma","year":"2010","journal-title":"Cancer"},{"issue":"8","key":"2019111822434659800_B116","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1038\/sj.leu.2403399","article-title":"Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia.","volume":"18","author":"Terre","year":"2004","journal-title":"Leukemia"},{"issue":"5","key":"2019111822434659800_B117","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1182\/blood-2002-07-2053","article-title":"Emergence of clonal cytogenetic abnormalities in Ph\u2212 cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority.","volume":"101","author":"Bumm","year":"2003","journal-title":"Blood"},{"issue":"3","key":"2019111822434659800_B118","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/sj.leu.2403607","article-title":"Clonal aberrations in Philadelphia chromosome negative hematopoiesis in patients with chronic myeloid leukemia treated with imatinib or interferon alpha.","volume":"19","author":"Bacher","year":"2005","journal-title":"Leukemia"},{"issue":"8","key":"2019111822434659800_B119","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1182\/blood-2007-01-070045","article-title":"Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase.","volume":"110","author":"Jabbour","year":"2007","journal-title":"Blood"},{"issue":"15","key":"2019111822434659800_B120","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1182\/blood-2009-03-212969","article-title":"The derivation of diagnostic markers of chronic myeloid leukemia progression from microarray data.","volume":"114","author":"Oehler","year":"2009","journal-title":"Blood"},{"issue":"11","key":"2019111822434659800_B121","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1182\/blood.V92.11.4059","article-title":"Response at three months is a good predictive factor for newly diagnosed chronic myeloid leukemia patients treated by recombinant interferon-alpha.","volume":"92","author":"Mahon","year":"1998","journal-title":"Blood"},{"key":"2019111822434659800_B122","article-title":"Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML) [published online ahead of print March 26, 2012].","author":"Hanfstein","journal-title":"Leukemia"},{"issue":"3","key":"2019111822434659800_B123","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","article-title":"Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.","volume":"30","author":"Marin","year":"2012","journal-title":"J Clin Oncol"},{"issue":"17","key":"2019111822434659800_B124","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1182\/blood-2011-04-348110","article-title":"The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors.","volume":"118","author":"Jabbour","year":"2011","journal-title":"Blood"},{"issue":"6","key":"2019111822434659800_B125","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1182\/blood-2010-07-293977","article-title":"Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure.","volume":"117","author":"Jabbour","year":"2011","journal-title":"Blood"},{"issue":"26","key":"2019111822434659800_B126","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1056\/NEJMoa1004095","article-title":"Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.","volume":"363","author":"Preudhomme","year":"2010","journal-title":"N Engl J Med"},{"issue":"12","key":"2019111822434659800_B127","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1182\/blood-2011-02-336685","article-title":"Combination of pegylated IFN-alpha2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia.","volume":"118","author":"Simonsson","year":"2011","journal-title":"Blood"},{"issue":"24","key":"2019111822434659800_B128","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"issue":"24","key":"2019111822434659800_B129","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"issue":"11","key":"2019111822434659800_B130","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1038\/leu.2009.168","article-title":"Harmonization of molecular monitoring of CML therapy in Europe.","volume":"23","author":"M\u00fcller","year":"2009","journal-title":"Leukemia"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/120\/4\/737\/1498447\/zh803012000737.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/120\/4\/737\/1498447\/zh803012000737.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T22:18:51Z","timestamp":1713997131000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/120\/4\/737\/105617\/How-I-treat-CML-blast-crisis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,26]]},"references-count":130,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,7,26]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2012-03-380147","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7,26]]}}}